Takeda Pharmaceutical Company Limited and Perrigo Company plc: A Comprehensive Revenue Analysis

Pharmaceutical Revenue Trends: Takeda vs. Perrigo

__timestampPerrigo Company plcTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201440608000001777824000000
Thursday, January 1, 201546039000001807378000000
Friday, January 1, 201652806000001732051000000
Sunday, January 1, 201749462000001770531000000
Monday, January 1, 201847317000002097224000000
Tuesday, January 1, 201948374000003291188000000
Wednesday, January 1, 202050633000003197812000000
Friday, January 1, 202141387000003569006000000
Saturday, January 1, 202244516000004027478000000
Sunday, January 1, 202346556000004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the ever-evolving pharmaceutical industry, Takeda Pharmaceutical Company Limited and Perrigo Company plc stand as titans, each with a unique trajectory. Over the past decade, Takeda has demonstrated a remarkable growth, with its revenue surging by approximately 140% from 2014 to 2023. This growth is highlighted by a significant leap in 2019, where revenues jumped by over 80% compared to the previous year, marking a pivotal moment in Takeda's expansion strategy.

Conversely, Perrigo's revenue has shown a more stable pattern, with fluctuations around the $4.5 billion mark. Despite a slight dip in 2021, Perrigo's revenue rebounded by 2023, reflecting its resilience in a competitive market. Notably, the data for 2024 is incomplete, leaving room for speculation on future trends. This analysis underscores the dynamic nature of the pharmaceutical sector and the strategic maneuvers of its key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025